PharmiWeb1h
The Menninger Clinic Offering Nation’s First Rapid Targeted Transcranial Magnetic Stimulation to Treat Depression
Menninger is the only hospital in the U.S. to offer groundbreaking treatment HOUSTON, TX / ACCESSWIRE / November 13, 2024 / ...
PharmiWeb2h
GAT Sport(R) Makes Triumphant Return to GNC, Launching All-New Nitraflex(R) ULTRA Pre-Workout
GAT Sport® Reclaims GNC Shelves and Introduces Its Newest Nitraflex® ULTRA Pre-Workout in a Power Play That Strengthens Both ...
PharmiWeb15h
CBD Life Sciences Inc. (CBDL) Applies for Beer & Liquor License to Sell CBD Wine
Company is creating its own wine. Capitalizing on the projected $2.1 billion U.S. CBD-infused beverage market by 2025, CBDL ...
PharmiWeb1m
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel
Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that it has expanded its leadership team with the appointments of Jan ...
PharmiWeb9h
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ...
PharmiWeb4h
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...
PharmiWeb1h
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global ...
PharmiWeb2h
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
Taiwan regulatory approval for the trial expected in Q1 2025Remains committed to a capital-efficient business strategySAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Ainos, Inc.
PharmiWeb1h
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indicationsOngoing progress towards first in human clinical study for ...
PharmiWeb1h
KindlyMD(R) Announces Third Quarter 2024 Financial Results
SALT LAKE CITY, UT / ACCESSWIRE / November 13, 2024 / ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company redefining value-based care and ...
PharmiWeb7h
Jaguar Health Reports Third Quarter 2024 Financial Results
The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 ...
PharmiWeb15h
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...